EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial

Nathaniel M Schuster iD, Mark S Wallace, Thomas D Marcotte, Dawn C Buse, Euyhyun Lee, Lin Liu, Michelle Sexton

Headache: The Journal of Head and Face Pain · 2026-02 · 66 (2) · 365-376

DOI: 10.1111/head.70025 ↗

At a glance

Randomisierte kontrollierte Studie in Headache: The Journal of Head and Face Pain, published online on 2025-12-30. Written by Nathaniel M Schuster and 6 co-authors. Institution: Center for Pain Management, Department of Anesthesiology, University of California San Diego Health System, La Jolla, California, USA. Major MEDLINE topics: Migraine Disorders, Cannabidiol, Dronabinol, Medical Marijuana. Cited 7 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NINDS NIH HHS, NCCIH NIH HHS, NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

To assess the efficacy of cannabis for the treatment of acute migraine.

Background

Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine.

Methods

In this randomized, double‐blind, placebo‐controlled, crossover trial, adults with migraine treated up to four separate migraine attacks, one each with vaporized (1) 6% Δ9‐tetrahydrocannabinol (THC) (THC‐dominant), (2) 11% cannabidiol (CBD) (CBD‐dominant), (3) 6% THC + 11% CBD, and (4) placebo cannabis flower in a randomized order. Washout period between treated migraine attacks was ≥1 week. The primary endpoint was pain relief, and secondary endpoints were pain freedom and most bothersome symptom freedom, all assessed at 2‐h post‐vaporization.

Results

Ninety‐two participants were enrolled and randomized, and 247 migraine attacks were treated. THC + CBD was superior to placebo at achieving pain relief (67.2% vs. 46.6%, odds ratio [95% confidence interval] 2.85 [1.22, 6.65], p = 0.016), pain freedom (34.5% vs. 15.5%, 3.30 [1.24, 8.80], p = 0.017), and most bothersome symptom freedom (60.3% vs. 34.5%, 3.32 [1.45, 7.64], p = 0.005) at 2 h, as well as sustained pain freedom at 24 h and sustained most bothersome symptom freedom at 24 and 48 h. THC‐dominant was superior to placebo for pain relief (68.9% vs. 46.6%, 3.14 [1.35, 7.30], p = 0.008) but not pain freedom or most bothersome symptom freedom at 2 h. CBD‐dominant was not superior to placebo for pain relief, pain freedom, or most bothersome symptom freedom at 2 h. There were no serious adverse events.

Conclusion

Acute migraine treatment with 6% THC + 11% CBD was superior to placebo at 2‐h post‐treatment with sustained benefits at 24 and 48 h.

Subjects

MeSH terms (MEDLINE)

Migraine DisordersCannabidiolDronabinolMedical MarijuanaHumansDouble-Blind MethodCross-Over StudiesMaleAdultFemaleMiddle AgedYoung AdultTreatment OutcomeAcute Disease

Author keywords

acutecannabidiolcannabinoidscannabismigraineΔ9‐tetrahydrocannabinol

Substances

CannabidiolDronabinolMedical Marijuana

Authors and institutions

  • Center for Pain Management, Department of Anesthesiology, University of California San Diego Health System, La Jolla, California, USA.
  • Center for Medicinal Cannabis Research, University of California San Diego Health System, San Diego, California, USA.
  • Department of Psychiatry, University of California San Diego Health System, San Diego, California, USA.
  • Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla, California, USA.
  • Department of Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, USA.

ORCID profiles: Nathaniel M Schuster

Funding

  • NINDS NIH HHS
  • NCCIH NIH HHS
  • NIH HHS
  • NCATS NIH HHS
  • Migraine Research Foundation
  • Academic Senate, University of California, San Diego
  • Academic Senate, University of California, Riverside
  • National Institutes of Health

Cite

APA

Schuster, N. M., Wallace, M. S., Marcotte, T. D., Buse, D. C., Lee, E., Liu, L., & Sexton, M. (2026). Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial. Headache: The Journal of Head and Face Pain, 66(2), 365-376. https://doi.org/10.1111/head.70025

Vancouver

Schuster NM, Wallace MS, Marcotte TD, Buse DC, Lee E, Liu L, et al. Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial. Headache: The Journal of Head and Face Pain. 2026;66(2):365-376. doi:10.1111/head.70025

BibTeX
@article{Schuster2026,
  author = {Schuster, Nathaniel M and Wallace, Mark S and Marcotte, Thomas D and Buse, Dawn C and Lee, Euyhyun and Liu, Lin and Sexton, Michelle},
  title = {Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  volume = {66},
  number = {2},
  pages = {365--376},
  doi = {10.1111/head.70025}
}
Start for free →